Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 31;14(8):1415-1417.
doi: 10.21037/gs-2025-240. Epub 2025 Aug 25.

Reevaluating regional nodal irradiation after nodal pathologic complete response to neoadjuvant chemotherapy: toward individualized de-escalation

Janhavi Venkataraman  1 , Kefah Mokbel  1
Affiliations
Editorial

Reevaluating regional nodal irradiation after nodal pathologic complete response to neoadjuvant chemotherapy: toward individualized de-escalation

Janhavi Venkataraman et al. Gland Surg. .
No abstract available

Keywords: Breast cancer; neoadjuvant chemotherapy (NAC); pathological complete response; regional nodal irradiation (RNI); treatment de-escalation.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://gs.amegroups.com/article/view/10.21037/gs-2025-240/coif). K.M. received fees from Merit Medical and Q Medical Technologies corporations. The other author has no conflicts of interest to declare.

Comment on

  • Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
    Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Lucas PC, Gupta N, Li XA, McCormick B, Smith B, Tendulkar RD, Kavadi VS, Matsumoto K, Seaward SA, Irvin WJ Jr, Lin JY, Mutter RW, Muanza TM, Stromberg J, Jagsi R, Weiss AC, Curran WJ Jr, Wolmark N. Mamounas EP, et al. N Engl J Med. 2025 Jun 5;392(21):2113-2124. doi: 10.1056/NEJMoa2414859. N Engl J Med. 2025. PMID: 40466065 Free PMC article. Clinical Trial.

References

    1. Mamounas EP, Bandos H, White JR, et al. Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy. N Engl J Med 2025;392:2113-24. 10.1056/NEJMoa2414859 - DOI - PMC - PubMed
    1. Ito M, Amari M, Sato A, et al. Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy. Breast 2024;73:103604. 10.1016/j.breast.2023.103604 - DOI - PMC - PubMed
    1. Chen YY, Ge JY, Ma D, et al. Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer. Front Oncol 2020;10:570981. 10.3389/fonc.2020.570981 - DOI - PMC - PubMed
    1. Varghese J, Patani N, Wazir U, et al. Wire-Free Targeted Axillary Dissection: A Pooled Analysis of 1300+ Cases Post-Neoadjuvant Systemic Therapy in Node-Positive Early Breast Cancer. Cancers (Basel) 2024;16:2172. 10.3390/cancers16122172 - DOI - PMC - PubMed
    1. Alliance for Clinical Trials in Oncology. A011202: A randomized phase III trial evaluating the role of axillary lymph node dissection in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy. Available online: https://clinicaltrials.gov/ct2/show/NCT01901094

LinkOut - more resources